Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024623 (
gastric cancer
)
36,219
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Three cases of multicentric reticulohistiocytosis showing typical clinical, histologic, and ultrastructural findings are reported. In one,
gastric cancer
occurred; in the other two cases, severe polyarthritis was the only detectable internal involvement. The serine proteinases, urokinase and tissue-type plasminogen activator, were evaluated both with the autohistographic technique and spectrophotometric assay in lesional skin and synovia.
Urokinase
levels appeared grossly increased in the lesional synovia and moderately increased in the lesional skin. We suggest that urokinase, presumably released by the activated proliferating histiocytes, may play a major role in the extracellular matrix degradation leading to erosion of cartilage and adjacent bone in multicentric reticulohistiocytosis.
...
PMID:Multicentric reticulohistiocytosis. Report of three cases with the evaluation of tissue proteinase activity. 314 26
The effect of fibrinolytic agents, Tissue Culture
Urokinase
(TCUK) and Urinary
Urokinase
(UUK), was investigated in a total of 146 patients with
gastric cancer
, pulmonary cancer or breast cancer who received various anti-cancer agents, mainly MMC, in combination with the fibrinolytic agents. Assessments were made according to the Koyama-Saito criteria. In order to maintain impartiality of this comparative trial, the drugs were randomly administered to the patients by a card system. The patients who died during the study were excluded from the analysis and the patients with colorectal cancer were also excluded because this disease was not included in the study protocol. As a result, 51 patients given TCUK and 50 patients given UUK (101 in total) were subjected to analyse. The response rate (CR + PR/No. of admitted patients) was 15.6% (8/51) for the TCUK group and 10.0% (5/50) for the UUK group respectively. The patients with measurable lesions in the TCUK group showed a response rate of 25.9% (7/27) and those in the UUK group, 14.3% (4/28). Side effects were observed in 52.1% of patients in the TCUK group and 47.9% in the UUK group. However, these symptoms were related to the anti-cancer agents. Neither a tendency to hemorrhage nor allergic symptoms occurred in association with the two fibrinolytic agents, TCUK and UUK. to UUK in terms of an activity to enhance the chemotherapeutic effect of anti-cancer agents and that combination use of TCUK and anti-cancer agents seems to be useful.
...
PMID:[Clinical evaluation of various antineoplastic agents combined with urokinase--a comparison between urokinase from tissue culture (TCUK) and urine-derived urokinase (UUK)]. 682 Sep 18
Urokinase
plasminogen activating system (PA system) and vascular endothelial growth factor (VEGF) were recently suggested to contribute synergistically to tumor progression. To evaluate the roles of the PA system and VEGF in
gastric cancer
, the effects of the PA system and VEGF on tumor angiogenesis and the survival of patients with
gastric cancer
were investigated. Cancer tissues from 101
gastric cancer
patients were assayed immunohistochemically for expression of urokinase-type plasminogen activator (uPA), uPA receptor (uPAR), PA inhibitor-1 (PAI-1) and VEGF protein. The positive rates of uPA, uPAR, PAI-1, VEGF expression were 22.8%, 32.7%, 36.6% and 26.7%, respectively. Positive staining was observed in tumor cells (uPA, uPAR, VEGF), or in both tumor cells and stromal cells (PAI-1). The expressions of uPA, uPAR, PAI-1 and VEGF were significantly correlated with the clinicopathological factors: uPA, depth of tumor invasion, differentiation, lymphatic and vascular invasion; uPAR, tumor size, depth, lymph node involvement, differentiation, vascular invasion; PAI-1, tumor size, depth, lymph node involvement, differentiation, vascular invasion; VEGF, differentiation, vascular invasion. The microvessel density (MVD) assessed immunohistochemically was significantly higher in the patients with expression of uPA, uPAR or VEGF, and stepwise analysis identified uPA as an independent correlated factor with MVD. Furthermore, multivariate analysis demonstrated that depth of tumor invasion, lymph node involvement and uPA expression were independent prognostic factors. uPA is a key factor in the PA system, being associated with a poor outcome of
gastric cancer
, and contributing not only to invasive activity, but also to angiogenesis.
...
PMID:Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. 1270 73
Urokinase
(uPA) and its receptor (uPAR) play an important role in tumor growth and metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumors. In this study, ATF-Fc, an antibody-like molecule comprising the amino-terminal fragment of human uPA (ATF) linked to the Fc fragment of human IgG1 via a flexible linker was developed. Its antitumor activities were evaluated in vitro and in vivo. The results showed that ATF-Fc had obvious cytotoxic effect on several types of tumor cells, which is dependent on cellular expression of uPAR and its Fc fragment. Treatment with ATF-Fc caused a significant suppression on tumor growth and metastasis of xenograft human tumors (MCF-7 breast cancer and BGC-823
gastric cancer
) in athymic nude mice. Furthermore, we demonstrated that ATF-Fc had an anti-angiogenesis activity both in vitro and in vivo. In conclusion, we provided a novel therapeutic antibody-like molecule in the management of a variety of solid tumors by disrupting the uPA/uPAR interaction.
...
PMID:Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. 1875 23